



Faculty

Facilitator



Gunar Stemer (Austria)
Vienna General Hospital
Medical University Campus

Moderator



Anthony Sinclair (U.K.)
Birmingham Children's Hospital NHS
Foundation Trust and Aston University

Speakers



Sabine Eichinger (Austria)
Medical University of Vienna



Marianne Klemp (Norway)
Norwegian Knowledge Centre for
the Health Services (NOKC)




Duncan McRobbie (U.K.)
Guy's and St. Thomas' NHS
Foundation Trust

The EAHP invites you to attend the 2014 Synergy Satellite event

Anticoagulants – a matter of heart! Towards a bright future?

Wednesday, 26 March 2014, 11:30 – 13:00
Room 117

19th Congress of the EAHP
Centre de Convencions Internacional de Barcelona



G.GM.XA.12.2013.0305



This is an independent educational activity supported by an unrestricted educational grant from Bayer Pharmaceuticals.
The content of the scientific programme has not been influenced in any way by the sponsor.

© Bayer HealthCare Pharmaceuticals January 2014

Anticoagulants – a matter of heart!

Towards a bright future?

Programme

11:30 – 11:35	Introduction Gunar Stemer (Facilitator)
11:35 – 11:45	Programme pre-assessment survey Anthony Sinclair (Moderator)
11:45 – 12:10	Clinical issues – which drug for which patient Sabine Eichinger
12:10 – 12:35	The drugs don't work if the patients don't take them – improving patient adherence Duncan McRobbie
12:35 – 13:00	Economic evaluation of oral anticoagulants for atrial fibrillation Marianne Klemp

Teaching Goals

- ◆ Illustrate clinical decision criteria how to choose among the available novel oral anticoagulants in terms of efficacy and safety
- ◆ Present selected issues of patient education with regard to the available novel oral anticoagulants
- ◆ Discuss novel oral anticoagulants in terms of value for money

Learning Objectives

After the seminar the participants should be able to:

- ◆ Recall the most important efficacy and safety issues in order to distinguish among the available novel oral anticoagulants
- ◆ Outline the most important educational aspects in daily practice with regard to the available novel oral anticoagulants
- ◆ Describe key issues regarding cost-effectiveness of the available novel oral anticoagulants

